On valuing biopharmaceutical product pipelines: an effectuation model and evidence

Springer Science and Business Media LLC - Tập 4 - Trang 1-19 - 2015
Mark J. Ahn1, Anne S. York2, Wei Wu3, Yulianto Suharto1, Tugrul Daim1
1Portland State University, Portland, USA
2Creighton University, Omaha, USA
3Willamette University, Salem, USA.

Tóm tắt

New creative approaches are needed to manage emerging biotechnology innovations, regulations, and payor environments to enhance product pipeline productivity, valuation, and risk management. Biopharmaceutical firms must make dynamic resource allocation decisions on their relative levels of internal R&D and external strategic alliances in furthering their pipelines. As the predominant method of using discounted cash flow (DCF) methodologies may lead to chronic underinvestment and performance, we evaluated the integration of traditional DCF with an effectuation model of analysis. Unlike traditional financial models that begin with the end goal of assumed known cash flows and recursively solve for portfolio optimization, the effectuation model—means, affordable loss, partnerships, and expect the unexpected—begins with resources that are readily available to the firm and then seeks to maintain strategic flexibility to take advantage of environmental contingencies as they arise. Using effectuation principles can provide insight into optimizing pipeline decisions by focusing on the logic of control rather than the logic of prediction. Using empirical data, we found that investors were able to effectively differentiate between the pipeline values of among companies. Overall, these results suggest that the integration of effectuation and DCF provides a lens from which to explore emerging varieties of small and large company innovation in the biopharmaceutical industry.

Tài liệu tham khảo

Afifi, A. A. A., & Clark, V. A. (2004). Computer-aided multivariate analysis (Vol. 62). CRC Press: Boca Raton.

Ahn, M. J., & Meeks, M. (2008). Building a conducive environment for life science-based entrepreneurship and industry clusters. Journal of Commercial Biotechnology, 14(1), 20–30.

Ahn, M. J., Meeks, M., Davenport, S., & Bednarek, R. (2010). Exploring technology agglomeration patterns for multinational pharmaceutical and biotechnology firms. Journal of Commercial Biotechnology, 16(1), 17–32.

Ahn, M. J., Wu, W., & Rahman, Q. (2010). Medarex: realizing its potential? In M. J. Ahn, M. A. Alvarez, A. D. Meyers, & A. S. York (Eds.), Building the case for biotechnology. Logos Press: Washington, DC.

Augier, M., & Sarasvathy, S. D. (2004). Integrating evolution, cognition and design: extending Simonian perspectives to strategic organization. Strategic Organization, 2(2), 169–204.

Barney, J. (1991). Firm resources and sustained competitive advantage. Journal of Management, 17(1), 99–120.

Beach, R. (2011). Microcap pharmaceutical firms: linking drug pipelines to market value. Journal of Health Care Finance, 39(2), 82–92.

Brettel, M., Mauer, R., Engelen, A., & Küpper, D. (2012). Corporate effectuation: entrepreneurial action and its impact on R&D project performance. Journal of Business Venturing, 27(2), 167–184.

Brink, J., & Holmén, M. (2009). Capabilities and radical changes of the business models of new bioscience firms. Creativity and Innovation Management, 18(2), 109–120.

Darlington, R. B., Weinberg, S. L., & Walberg, H. J. (1973). Canonical variate analysis and related techniques. Review of Educational Research, 43(4), 433–454.

Dew, N., Sarasvathy, S. D., & Venkataraman, S. (2004). The economic implications of exaptation. Journal of Evolutionary Economics, 14(1), 69–84.

DiMasi, J. A. (2013). Clinical success rates for new cancer drugs doubled from the mid-1990s to early-2000s. Retrieved August 10, 2013, from http://csdd.tufts.edu.

Fan, X. (1997). Canonical correlation analysis and structural equation modeling: what do they have in common? Structural Equation Modeling: A Multidisciplinary Journal, 4(1), 65–79.

Fernandez, S., & Arabi, A. (2013). Azn/lower EPS reflects higher spend; pipeline visibility a key focus/market perform. Retrieved August 16, 2013, from http://portal.leerink.com/.

Ford, C. M., Sharfman, M. P., & Dean, J. W. (2008). Factors associated with creative strategic decisions. Creativity and Innovation Management, 17(3), 171–185.

Gulati, R., & Higgins, M. C. (2003). Which ties matter when? The contingent effects of interorganizational partnerships on IPO success. Strategic Management Journal, 24(2), 127–144.

Hair, J. F., Jr., Anderson, R. E., & Tatham, R. L. (1986). Multivariate data analysis with readings. Macmillan Publishing Co., Inc: New York.

Harrison, M., & Lerer, L. (2002). Real options for biotechnology valuation. Nature Biotechnology, 20(3), 223–223.

Hartmann, M., & Hassan, A. (2006). Application of real options analysis for pharmaceutical R&D project valuation—empirical results from a survey. Research Policy, 35(3), 343–354.

Hemlin, S. (2009). Creative knowledge environments: an interview study with group members and group leaders of university and industry R&D groups in biotechnology. Creativity and Innovation Management, 18(4), 278–285.

Hemphälä, J., & Magnusson, M. (2012). Networks for innovation—but what networks and what innovation? Creativity and Innovation Management, 21(1), 3–16.

Hitt, M. A., & Duane, R. (2002). The essence of strategic leadership: managing human and social capital. Journal of Leadership & Organizational Studies, 9(1), 3–14.

Iskin, I., Daim, T. U., & Cutar, A. (2011). Do investments in research and development translate to sales? International Journal of Business Innovation and Research, 5(5), 510–525.

Kirchhoff, M., & Schiereck, D. (2011). Determinants of M&A success in the pharmaceutical and biotechnological industry. IUP Journal of Business Strategy, 8(1).

Kola, I., & Landis, J. (2004). Can the pharmaceutical industry reduce attrition rates? Nature Reviews Drug discovery, 3(8), 711–716.

Kumaraswamy, A. (1998). An organizational real-options perspective of firms’ R&D: Empirical evidence. Chicago: Paper presented at the 2nd Annual Conference on Real Options: theory meets practice.

Levine, M.S. (1977). Canonical analysis and factor comparison (Vol. 6). Sage

Lindgren, M., & Packendorff, J. (2011). Issues, responsibilities and identities: a distributed leadership perspective on biotechnology R&D management. Creativity and Innovation Management, 20(3), 157–170.

Löfqvist, M. (2009). On the valuation of “big pharma’s” research pipelines.

Makadok, R. (2001). Toward a synthesis of the resource‐based and dynamic‐capability views of rent creation. Strategic Management Journal, 22(5), 387–401.

Newton, D. P., Paxson, D. A., & Widdicks, M. (2004). Real R&D options. International Journal of Management Reviews, 5(2), 113–130.

Nicholson, S., Danzon, P. M., & McCullough, J. S. (2002). Biotech-pharmaceutical alliances as a signal of asset and firm quality: National Bureau of Economic Research.

Nickisch, K., & Bode-Greuel, K. M. (2013). NPV modelling for the selection of value-creating biosimilar development candidates. Journal of Commercial Biotechnology, 19(1).

Pammolli, F., Magazzini, L., & Riccaboni, M. (2011). The productivity crisis in pharmaceutical R&D. Nature Reviews Drug Discovery, 10(6), 428–438.

Pavlou, A. K., & Belsey, M. J. (2005). Biopharma licensing and M&A trends. Nature Reviews Drug Discovery, 4(4), 273–274.

Pedhazur, E. J. (1997). Multiple regression in behavioral research: explanation and prediction.

Piccart-Gebhart, M. J. (2014). The 41st David A. Karnofsky memorial award lecture: academic research worldwide—quo vadis? Journal of Clinical Oncology, 32(4), 347–354.

President’s Council of Advisors on Science and Technology. (2012). President’s council of advisors on science and technology: propelling innovation in drug discovery, development, and evaluation—policy and medicine. Retrieved August 6, 2013, from http://www.policymed.com/

Read, S., Dew, N., Sarasvathy, S. D., Song, M., & Wiltbank, R. (2009). Marketing under uncertainty: the logic of an effectual approach. Journal of Marketing, 73(3), 1–18.

Roy, A. (2012). Stifling new cures: the true cost of lengthy clinical drug trials. Project FDA report. New york: Manhattan Institute for Policy Research, 5.

Sarasvathy, S. D. (2001). Causation and effectuation: toward a theoretical shift from economic inevitability to entrepreneurial contingency. Academy of Management Review, 26(2), 243–263.

Sarasvathy, S. D. (2008). Effectuation: elements of entrepreneurial expertise. Edward Elgar Publishing: United Kingdom.

Sherry, A., & Henson, R. K. (2005). Conducting and interpreting canonical correlation analysis in personality research: a user-friendly primer. Journal of Personality Assessment, 84(1), 37–48.

Stewart, J. J., Allison, P. N., & Johnson, R. S. (2001). Putting a price on biotechnology. Nature Biotechnology, 19(9), 813–818.

Su, Y.-S., Tsang, E. W., & Peng, M. W. (2009). How do internal capabilities and external partnerships affect innovativeness? Asia Pacific Journal of Management, 26(2), 309–331.

Thompson, B. (1985). Heuristics for teaching multivariate general linear model techniques (Annual meeting of the American Educational Research Journal, Chicago, IL.(ERIC Document Reproduction Service No. ED 262 073)).

Thompson, B. (1991). A primer on the logic and use of canonical correlation analysis. Measurement and Evaluation in Counseling and Development, 24(2), 80–95.

Tucker, R., Chase, L., Monge, P., & Cappella, J. (1980). Canonical correlation (Multivariate techniques in human communication research, 205–228).

Wierenga, D. E., & Eaton, C. R. (2006). Drug development and approval process (USA). Retrieved Dec 17, 2009, from http://www.mr-tip.com/

Wiltbank, R., Read, S., Dew, N., & Sarasvathy, S. D. (2009). Prediction and control under uncertainty: outcomes in angel investing. Journal of Business Venturing, 24(2), 116–133.

York, A. S., Dunham, L. M., & Ahn, M. (2011). Vertical versus horizontal integration in the biopharma industry: the link between acquisition announcements and stock market performance. Advances in Mergers & Acquisitions, 10, 121–143.

Thông tin
Thông tin xuất bản

Springer Science and Business Media LLC

Tập 4

1-19

Thông tin tác giả